Scout Investments Inc. lifted its holdings in Incyte Corporation (NASDAQ:INCY) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,011 shares of the biopharmaceutical company’s stock after purchasing an additional 10,792 shares during the period. Scout Investments Inc. owned about 43,598.84% of Incyte Corporation worth $10,741,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in INCY. Fisher Asset Management LLC increased its stake in shares of Incyte Corporation by 3.2% in the 2nd quarter. Fisher Asset Management LLC now owns 15,532 shares of the biopharmaceutical company’s stock valued at $1,956,000 after purchasing an additional 482 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Incyte Corporation by 5.4% in the 2nd quarter. State of Alaska Department of Revenue now owns 2,292 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 117 shares in the last quarter. National Pension Service increased its stake in shares of Incyte Corporation by 17.2% in the 2nd quarter. National Pension Service now owns 151,900 shares of the biopharmaceutical company’s stock valued at $19,562,000 after purchasing an additional 22,342 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Incyte Corporation by 164.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 9,533 shares of the biopharmaceutical company’s stock valued at $1,200,000 after purchasing an additional 5,931 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its stake in shares of Incyte Corporation by 511.5% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 27,651 shares of the biopharmaceutical company’s stock valued at $3,482,000 after purchasing an additional 23,129 shares in the last quarter. Hedge funds and other institutional investors own 88.57% of the company’s stock.

In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total transaction of $8,421,463.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Paula J. Swain sold 20,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $140.00, for a total value of $2,800,000.00. Following the transaction, the executive vice president now owns 55,067 shares in the company, valued at $7,709,380. The disclosure for this sale can be found here. Insiders sold 102,062 shares of company stock worth $12,652,893 over the last quarter. 17.70% of the stock is currently owned by insiders.

Incyte Corporation (INCY) opened at $104.76 on Friday. Incyte Corporation has a twelve month low of $98.49 and a twelve month high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. During the same period in the prior year, the firm posted $0.19 earnings per share. The firm’s quarterly revenue was up 41.6% on a year-over-year basis. research analysts anticipate that Incyte Corporation will post -1.3 EPS for the current year.

INCY has been the subject of several recent analyst reports. Raymond James Financial, Inc. upgraded Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price target for the company in a research note on Monday, September 11th. J P Morgan Chase & Co restated a “buy” rating and issued a $149.00 price target on shares of Incyte Corporation in a research note on Thursday, August 31st. Oppenheimer Holdings, Inc. restated a “hold” rating and issued a $135.00 price target on shares of Incyte Corporation in a research note on Thursday, August 31st. BMO Capital Markets reiterated an “outperform” rating and set a $172.00 price objective on shares of Incyte Corporation in a research note on Monday, August 28th. Finally, Argus reiterated a “buy” rating and set a $150.00 price objective on shares of Incyte Corporation in a research note on Wednesday, September 13th. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $144.98.

WARNING: “Incyte Corporation (INCY) Position Boosted by Scout Investments Inc.” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/11/incyte-corporation-incy-position-boosted-by-scout-investments-inc.html.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.